Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration-Reference-Cited by-同舟云学术

Clinical features and associated factors of intraocular inflammation following intravitreal brolucizumab as switching therapy for neovascular age-related macular degeneration

Published:2023-03-27 Issue:8 Volume:261 Page:2359-2366
ISSN:0721-832X
Container-title:Graefe's Archive for Clinical and Experimental Ophthalmology
language:en
Short-container-title:Graefes Arch Clin Exp Ophthalmol

Author:

Sotani Rei,Matsumiya Wataru^ORCID,Kim Kyung Woo,Miki Akiko,Yasuda Eriko,Maeda Yoshifumi,Hara Rumiko,Kusuhara Sentaro,Nakamura Makoto

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology

Link

https://link.springer.com/content/pdf/10.1007/s00417-023-06036-x.pdf

Reference33 articles.

1. Bobadilla M, Pariente A, Oca AI, Peláez R, Pérez-Sala Á, Larráyoz IM (2022) Biomarkers as Predictive Factors of Anti-VEGF Response. Biomedicines 10. https://doi.org/10.3390/biomedicines10051003

2. Dugel PU, Koh A, Ogura Y, Jaffe GJ, Schmidt-Erfurth U, Brown DM, Gomes AV, Warburton J, Weichselberger A, Holz FG (2020) HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology 127:72–84. https://doi.org/10.1016/j.ophtha.2019.04.017

3. Jain A, Chea S, Matsumiya W, Halim MS, Yaşar Ç, Kuang G, Sepah YJ, Khanani AM, Do DV, Nguyen QD (2020) Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep 18:100687. https://doi.org/10.1016/j.ajoc.2020.100687

4. Haug SJ, Hien DL, Uludag G, Ngoc TTT, Lajevardi S, Halim MS, Sepah YJ, Do DV, Khanani AM (2020) Retinal arterial occlusive vasculitis following intravitreal brolucizumab administration. Am J Ophthalmol Case Rep 18:100680. https://doi.org/10.1016/j.ajoc.2020.100680

5. Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, Rich R, Chaudhry N, Lakhanpal RR, Oellers PR, Leveque TK, Rutledge BK, Chittum M, Bacci T, Enriquez AB, Sund NJ, Subong ENP, Albini TA (2020) Retinal Vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology 127:1345–1359. https://doi.org/10.1016/j.ophtha.2020.04.017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Brolucizumab;Reactions Weekly;2023-11-25

2. Marked Choroidal Thinning Observed after Intravitreal Brolucizumab Injection;Case Reports in Ophthalmology;2023-11-14

3. Efficacy, Safety, and Durability of Brolucizumab: An 8-Month Post-Marketing Surveillance Analysis;Clinical Ophthalmology;2023-09